Navigation

Colorectal cancer (metastatic) - aflibercept [ID514]

Aflibercept for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy

Status: History
Expected date of issue: TBC
Referral date: February 2012
Process: STA
Notes:

Scoped as part of Batch 21

Topic area:
  • Cancer
  • Digestive system
 

NICE project team

Executive Lead: Carole Longson
Technical Lead: Kumar Perampaladas
Communications manager: Alice Law
Project manager:

Jeremy Powell

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 14 February 2013
1st appraisal committee meeting: 22 May 2013
2nd appraisal committee meeting 23 July 2013
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Sanofi (aflibercept)

Patient/carer groups

  • Beating Bowel Cancer

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency

Possible comparator manufacturer(s)

  • Actavis UK (irinotecan) (not participating)
  • Hospira UK (calcium folinate, irinotecan, fluorouracil) (not participating)
  • Medac UK (irinotecan, fluorouracil) (not participating)
  • Mylan (calcium folinate, irinotecan) (not participating)
  • Pfizer (irinotecan, calcium folinate, calcium levofolinate)
  • Roche (capecitabine)
  • Sandoz (irinotecan, calcium folinate, fluorouracil) (not participating)
  • Teva UK (irinotecan, calcium folinate) (not participating)
  • Wockhardt UK (calcium folinate, fluorouracil) (not participating)

Relevant research groups

Evidence Review Group

  • NHS Centre for Reviews and Dissemination, University of York
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • tbc

Top


 

Project history

Date Update
25 March 2014 TA307 Colorectal cancer (metastatic) - aflibercept published
24 October 2013 The FAD for the single technology appraisal of aflibercept for treating colorectal cancer [ID514] has been released to consultees and commentators only. It will not be placed on the NICE website at this time. This is because the text of the FAD includes information that is academic in confidence (yet to be published) that was discussed in the public Appraisal Committee meeting and is material to the Appraisal Committee's decision. We are taking this exceptional approach, because we want to proceed with this appraisal so that consultees and commentators are able to consider their response. The next steps of the process remain the same.
Top


 

Key documents

This page was last updated: 21 March 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.